

Bayesian analysis on smoking prevalence and age of smoking initiation in Nepalese population: Findings from the STEPS national surveys

Umesh R. Aryal¹, Dinesh Bhandari², Bihungum Bista³, Yogesh M. Shrestha⁴, Meghnath Dhimal³, Pradip Gyanwali³

AFFILIATION

1 Karnali Academy of Health Sciences, Jumla, Nepal

2 School of Nursing and Midwifery, University of Monash, Melbourne, Australia

3 Nepal Health Research Council, Ramshah Path, Kathmandu, Nepal

4 Tri-Chandra College, Department of Statistics, Tribhuvan University, Kirtipur, Nepal

CORRESPONDENCE TO

Umesh R. Aryal. Karnali Academy of Health Sciences, Chandannath

Popul. Med. 2024;6(August):23

21200, Jumla, Nepal. E-mail: aryalumes@gmail.com ORCID iD: <https://orcid.org/0000-0002-1809-4071>

KEYWORDS

prevalence, smoking initiation, Bayes factor, STEPS

Received: 8 January 2023, **Revised:** 25 July 2024, **Accepted:** 30 July 2024

<https://doi.org/10.18332/popmed/191814>

ABSTRACT

INTRODUCTION Smoking prevalence and age of smoking initiation (AOI) are two important variables for tobacco control programs. The study aimed to compare the prevalence of smoking between three WHO STEPS (STEPwise approach to surveillance) surveys and the AOI between males and females, using the Bayesian approach.

METHODS We made three null hypotheses (H_0) at a 5% level of significance: the smoking prevalence in the 2019 WHO STEPS survey is similar to the previous two surveys (2008 vs 2019, and 2013 vs 2019); mean AOI between males and females is similar within 2019 survey. Both classical and Bayesian hypotheses were tested. In the Bayesian hypothesis, the Bayes factor (BF) and robust analyses were performed through the Markov chain simulation-based estimation method.

RESULTS We found no difference in smoking prevalence

between the 2013 and 2019 surveys ($BF_{0.} = 56.59$). In contrast, there is strong evidence of the difference ($BF_{0.} = 2.38 \times 10^{-43}$) in smoking prevalence between the 2008 and 2019 surveys. Next, there is no evidence of a difference in the mean log AOI between males and females ($BF_{0.1} = 12.54$). The sequential analysis showed strong to very strong evidence for the H_0 for AOI ($BF_{10} < 1$) and smoking prevalence ($BF_{0.} > 1$), respectively.

CONCLUSIONS Our findings go beyond classical hypothesis testing on smoking behaviors and highlight the importance of the BF for the decision-making process in the tobacco control program. Further, the findings suggest that immediate efforts should be made to understand the underlying cause behind the stationary prevalence rate of the smoking population in the last five years.

INTRODUCTION

Tobacco use is an important risk factor for the growing burden of non-communicable diseases in Southeast Asia¹. More than 4000 people die every day due to tobacco use and secondhand smoke in the region¹. In Nepal, tobacco use has a high prevalence and is responsible for more than 27000 deaths annually². A review of the literature has shown the mean age of smoking initiation (AOI) ranged 10.2 to 18.6 years in different populations³. In the Nepalese population, those who initiated smoking before the age of 16 years were addicted to nicotine⁴.

The surgeon general report asserts that adolescents who initiated smoking at an early age were more likely to

be addicted to cigarettes and have more difficulty quitting in adulthood^{5,6}. The majority of Nepalese adults who smoke started smoking before the age of 18 years⁴. Adolescents are the entry point through which tobacco addiction enters the population⁵. There was evidence that AOI was linked with the risk of cardiovascular disease and lung cancer, and the high smoking prevalence is associated with sleep apnea syndrome⁷⁻⁹. Therefore, the age of smoking initiation and the smoking prevalence are two prime and crucial indicators for policymakers in tobacco control and public health⁶.

Most of the tobacco control studies published in scientific journals test the hypothesis using the frequentist approach^{10,11}. The frequentist approach estimates the p-value

which is the probability of obtaining the results, assuming the null hypothesis (H_0) is true¹²⁻¹⁶. This approach is based on the lower the p-value, the stronger the evidence against the null hypothesis. However, there is a practice of producing false positive results in scientific publications making statistical results significant ($p < 0.05$) rather than testing a hypothesis¹⁷. This misuse is wide spread at all levels and needs to be addressed^{18,19}. One of the alternatives to the p-value approach is the Bayesian approach which includes the Bayes factor (BF) that has been popular in recent years as a substitute for p-values by comparing their predicted success for observed data^{12-16,18-19}.

The study aims to compare the prevalence of smoking using the frequentist and the Bayesian approach for STEPS survey data of 2019 with STEPS survey data of 2008 and 2013²⁰⁻²². Similarly, a comparison of the age of smoking initiation across genders has also been examined for STEPS survey data 2019²⁰.

METHODS

Study design and sampling techniques

This is an analysis based on secondary data collected from the WHO STEPS survey 2008, 2013 and 2019 in Nepal to compare the smoking prevalence rate and mean age of smoking initiation²⁰⁻²². The STEPS survey is a nationally representative cross-sectional study carried out to collect up-to-date information on NCDs risk factors. In 2019, 5593 individuals from all seven provinces were selected by multistage cluster sampling. A total of 259 clusters/wards were selected as primary sampling units, maintaining 37 clusters from each province. From each cluster, 25 households were selected by using systematic sampling. One individual above 14 years and below 70 years was selected randomly and data were collected on Android tablets²⁰. In 2013, 4200 individuals aged 15–69 years were selected by multistage cluster sampling from 70 Ilakas of Nepal²². In 2008, 4328 respondents aged 15–64 years were selected from 15 districts of Nepal through cluster sampling²³. The detailed sampling strategy is available in the STEPS survey 2019 report²⁰⁻²².

Study variables

The following variables were selected as per the objective of the study²⁰⁻²². Current smoker was a person who has smoked tobacco products in the last 30 days. Based on current smoking behavior, smoking prevalence was computed. Sex as a variable, with males and females who have initiated smoking or smoked their first cigarette, and age of smoking initiation as the age of an individual who had initiated smoking or smoked his/her first cigarette.

The data on the current smoking rate were collected from STEPS survey 2008 and 2013 reports because of the unavailability of raw data. We extracted two variables, i.e. current smoking behavior and the age of smoking initiation from the STEPS survey 2019 data set available in the

supplementary section of the published article²³. Then, the statistical analysis was planned to compare the prevalence rate between surveys and the mean age of smoking initiation between males and females for the STEPS survey 2019²⁰.

Statistical analysis

Both frequentist and Bayesian approaches are applied to draw inferences on study variables. First, the following hypothesis is set up for the frequentist approach and later it is used for the Bayesian approach.

Hypothesis I

Null hypothesis (H_0): The smoking prevalence rates between 2013 and 2019 are similar ($H_0: \delta = 0$).

Alternative hypothesis (H_1): The smoking prevalence rate declined between 2013 and 2019 ($H_1: \delta < 0$).

Hypothesis II

Null hypothesis (H_0): The smoking prevalence rate is similar between 2008 and 2019 ($H_0: \delta = 0$).

Alternative hypothesis (H_1): The smoking prevalence rate declined between 2008 and 2019 ($H_1: \delta < 0$).

Hypothesis III

Null hypothesis (H_0): There is no difference in the mean age of smoking initiation between males and females (STEPS survey 2019) ($H_0: \delta = 0$). Alternative hypothesis (H_1): There is a difference in the mean age of smoking initiation between males and females (STEPS survey 2019) ($H_1: \delta \neq 0$).

In the above, δ is the difference in proportion or effect size.

For the frequentist approach, the proportion test and t-test were applied for smoking prevalence and AOI, respectively. The p-value was set at 0.05. A p-value is a conditional probability where its calculation is based on an assumption that H_0 is true, i.e. $p(\text{Evidence} | H_0)$ ^{13,24,25}. Bayesian inference approach focuses on the probability of statistical hypothesis given sample data, i.e. $p(H_i | \text{Evidence})$. The Bayes factor measures the odds favoring the alternative hypothesis against the null hypothesis and vice versa^{12-16,26}. The Bayes factor can be computed for both two-tail and one-tail tests. For the two-tail test, the Bayes factor (BF_{01}) represents a test of the null hypothesis (H_0) against the alternative (H_1) hypothesis. Likewise, The BF_{10} represents a test of the H_1 against the H_0 . The BF_{10} is the ratio of 1 divided by BF_{01} , i.e. $BF_{10} = 1/BF_{01}$. For the one-tail test, the following Bayes factor is computed and presented: BF_{0+} (H_0 vs H_{1+}) and BF_{0-} (H_0 vs H_{1-}) and vice versa. Bayes factors range from 0 to ∞ , and a Bayes factor of 1 indicates that both hypotheses predicted the data equally well²⁶. If the values are above 1 for B_{10} , the data provide evidence for the null hypothesis. For example, if the value of B_{10} is 3, then the data are three times more likely under H_1 than H_0 ²⁶. Alternatively, data supporting the null or alternative hypothesis can be visually presented using the probability wheel or pizza plot shown in Supplementary file

Figure 1²⁶. The Bayes factor explains how the prior beliefs about the value of parameter θ change into posterior beliefs about the value of parameter θ . The posterior distribution can be summarized by a 95 % credible interval for the amount of change or effect size (δ)^{13, 24-28}.

We tested hypotheses by computing BF_{0_0} and BF_{0_1} for the proportion of smoking and mean AOI, respectively. We have also presented a 95% credible limit for the posterior median effect size for both mean and proportion.

Sequential analysis is a robust visual analysis technique to monitor the sampling plan in the original research and provides evidence as the data accumulates²⁷. This output figure of sequential analysis also provides information on the convergence of the BF for the different sample sizes which helps either to stop collecting data when a pre-defined BF is achieved²⁷. The decision on evidence is made through the BF value equal to 1. The plot provides types of evidence for the hypothesis from anecdotal to very strong depending upon the value of the Bayes factor²⁷. The analysis for continuous variable provides 4 prior widths with their default values (r) of Cauchy distribution: maximum attainable Bayes factor, user prior ($r=0.707$), wide prior ($r=1$), and ultra-wide prior ($r=1.414$) which implies robustness^{17,26,27}. A default Cauchy prior value was set at $r=1/\sqrt{2}$ or 0.707 for this analysis²⁶.

The raincloud plot was constructed to check the normality of continuous data, i.e. AOI. The data were found skewed and hence transformed to $\log_{10}(N)$ to make the distribution normal²⁸. Next, we also computed the value of skewness to check the normality of the data. The value lies between -1 to 1 indicating the data are normal. All these statistical analyses were performed using JASP open-sourced software which is free, friendly and flexible with its default setting for Bayesian analysis²⁶. JASP software performed Bayesian analysis through the Markov chain simulation-based estimation method^{26,27}. As STEPS survey 2008 collected data for ages 18–64 years, we have extracted data from STEPS survey 2019 for the age group 15–64 too, so that a comparison can be made with that of STEPS survey 2008, this way we obtained the sample size of 5281 for 2019, though the sample size reported for this survey was 5593. We were unable to perform a Bayesian analysis between STEPS survey 2008 and 2013 because of the inaccessibility of raw data for 2013.

Ethical considerations

This study utilized publicly accessible de-identified secondary data from nationally representative surveys conducted in 2008, 2013, and 2019²⁰⁻²². The survey had taken written consent from each participant. If the study participants were under 18 years of age, an assent form was used and permission was taken from their guardians. Each participant's privacy was protected at all times.

RESULTS

Smoking behavior of respondents

The STEPS survey 2019 reports a prevalence of 17.1%

(SE=1.0) when considering the tobacco smoking age group 15–69 years ($n=5593$). To square the age group 15–64 years considered in STEPS survey 2008 data for the age group 15–64 years ($n=5281$) has been retained, which yielded a prevalence of 16.6% (SE=1.0) for the respondents who smoked tobacco products. The previous two STEPS surveys reported 18.5% (2013) and 26.2% (2008) of the respondents who smoked tobacco products. Comparing both surveys, the prevalence of smoking declined by 1.4% (2013 vs 2019, $p=0.86$) and 9.6% (2008 vs 2019, $p<0.001$).

Hypothesis I: Comparison of the smoking prevalence between 2013 and 2019 surveys

When the smoking prevalence for 2019 is compared with the smoking prevalence for 2013 (17.1% vs 18.5%, Bayesian hypothesis: $H_0: \delta=0$ vs $H: \delta<0$), the BF_{0_0} is found to be 56.59. It means the results are in favor of the null hypothesis by a factor of 57 compared to the alternative hypothesis. Supplementary file Figure 2 shows the posterior effect size of 0.183 (median) with a 95% credible interval (0.173–0.195). The grey dot in the prior line is below that of the posterior line (Supplementary file Figure 2) which represents that there is evidence in favor of the null hypothesis. The probability of the wheel also explains there is evidence to support the strong null hypothesis (i.e. nearly equal to 1/30 in the graph of Supplementary file Figure 2). Further, the sequential analysis (Supplementary file Figure 3) supports these results by showing very strong evidence for the null hypothesis because the Bayes factor lies above 1 and below 1000.

Hypothesis II: Comparison of the smoking prevalence between 2008 and 2019 surveys

The smoking prevalence for 2019 is found to be lower compared with smoking prevalence of 2008 (16.6% vs 26.2%, Bayesian hypothesis: $H_0: \delta=0$ vs $H: \delta<0$), the Bayesian factor (BF_{0_0}) is found to be 2.38×10^{-43} which is essentially zero indicating evidence in favor of the alternative hypothesis (Supplementary file Figure 4). It means the prevalence of smoking declined by 10 over the 10-year period. The posterior median effect size is 0.182 with a 95% credible limit of 0.172–0.193. The grey dot of the prior distribution line is above that of the solid posterior line indicating the result is in favor of the alternative hypothesis (Supplementary file Figure 4). The area covered by the probability of the wheel is similar to the area explained for $BF_{10}=30$ in Supplementary file Figure 1, which supports the alternative hypothesis. The sequential analysis (Supplementary file Figure 5) reveals there is strong evidence for the alternative hypothesis (H) because most of the values fall above 1.

Hypothesis III: Comparison of age of smoking initiation between males and females

Supplementary file Figure 6 shows the distribution of age

of smoking initiation of the respondents who currently smoke tobacco products for 2019. Most of the data are dispersed after 30 years for both males and females. These data are right-skewed for both males ($Sk=1.78$) and females ($Sk=1.83$). The median AOI is 17 (IQR: 15–20) years for both males ($n=630$) and females ($n=393$). After log-transformation, the distribution of AOI is normally distributed and the value of skewness lies between -1 and 1 (males: $Sk=0.18$; females: $Sk=0.38$) (Supplementary file Figure 7).

The mean log AOI for males and females was 1.24 (95% confidence limit: 1.23–1.25) and 1.24 (1.23–1.26), respectively. The frequentist approach shows that there is no difference in the mean log AOI between male and female respondents ($t= -0.46$, $df=1021$, $p=0.65$).

The BF_{01} is 12.54 which means nearly 13 times the results are produced in favor of the null hypothesis over the alternative hypothesis. In Supplementary file Figure 8, the grey dot in the solid line (posterior) is above the same dot in the dashed line indicating the data are in favor of the null hypothesis. The median posterior effect size is -0.03 (95% credible limit: -0.154–0.096). Supplementary file Figure 9 shows very strong evidence towards H_0 with a wide range of Bayes factor from 12.55 to 24.92 ($BF >10$ strongly supports H_0) having the different prior r , subsequently it shows strong evidence for the null hypothesis as the Bayes factor lies above 1.

DISCUSSION

The Bayesian approach has been widely used in the practice of medical research and tobacco control intervention^{12,29-30}. The present study provides valuable information on the application of Bayesian analysis which is useful for tobacco control strategy.

Our study has included two important variables of tobacco control measures, i.e. prevalence rate of smoking and age of smoking initiation. First, we compared smoking prevalence between three STEPS surveys from 2008 to 2019^{20,21}. The BF provided strong evidence for the alternative hypothesis, i.e. smoking prevalence declined between 2008 and 2019. During this period, the country has implemented various tobacco control programs such as health warning and advertisement bans, raising taxes on tobacco, a ban on the promotion and sponsorship of tobacco-related products, pictorial warnings in packages, and anti-tobacco campaigns^{3,31}. Although efforts to control tobacco use were implemented throughout the period, there was no apparent change in the prevalence of smoking during the latter half of 2013–2019. Political upheaval and close ties of politicians with the tobacco industry, and lack of coordination between different ministries, may be reasons for the unchanging smoking prevalence rate³²⁻³⁴. Further, this finding is particularly relevant for policymakers and stakeholders to identify the other causes behind it. Probably this demands in-depth and meticulous review and research.

Second, we compared the mean age (log age) of smoking initiation between males and females for the STEPS survey 2019. The BF indicates that the evidence is 13 times stronger in favor of the null hypothesis i.e. no difference in the mean age of smoking initiation. The policy-makers might use information about the relationship between smoking initiation and demographic factors to explore tailored interventions. Further studies could assess disparities in AOI based on factors such as gender, education level, place of residence, parental education, exposure to anti- and pro-tobacco messaging, tobacco-related knowledge, friends smoking, peer pressure, etc.^{35,36}.

Data were transformed to ensure that data met model assumptions necessary for both frequentist and Bayesian analysis, especially to confirm that the data were normally distributed. Our findings show both the frequentist and Bayesian approaches have similar results because of the large sample size and it provides the result for the parametric approach.

Strengths and limitations

The strengths of our study are that both traditional and Bayesian hypotheses were presented and compared; besides the Bayes factor, the effect sizes were presented with credible CI to evaluate how sensitive a study was to discover it; default prior values were used for analysis; the sample is random and representative of the Nepalese population; the age adjustment was done to perform frequentist and Bayesian analysis to compare the prevalence rate between STEPS surveys 2008 and 2019.

There are some limitations of the study. The high non-response rate, more representative of women and unequal classification of study area between surveys can influence the statistical inference that assumes perfectly random selection. Due to the paucity of raw data for STEPS survey 2013, it is not feasible to perform Bayesian analysis and the significant prevalence difference from the STEPS 2008 could not be determined. This study did not measure any confounding effects, such as sociodemographic variables, family history of smoking etc., that were associated with smoking prevalence and age of smoking initiation. Despite the limitations, the study has presented two important variables (smoking prevalence and age of smoking initiation) in the tobacco control programs.

CONCLUSIONS

When data on smoking prevalence and age of smoking initiation from a nationally representative sample were analyzed using a Bayesian method, more precise results were achieved, which are critical for reducing tobacco consumption as part of any preventive strategy. The findings of this study suggest that immediate efforts should be made to understand the underlying cause behind the stationary prevalence rate of the smoking population in the last five years.

REFERENCES

- World Health Organization. The fatal link between tobacco and cardiovascular diseases in the WHO South-East Asia Region. WHO; 2018. Accessed July 25, 2024. <https://apps.who.int/iris/handle/10665/273186>
- World Health Organization. Nepal Tobacco Fact-sheet 2018. WHO; 2018. Accessed July 25, 2024. https://apps.who.int/iris/bitstream/handle/10665/272687/wntd_2018_nepal_fs.pdf;jsessionid=5A799AF81B
- Khanal GN, Khatri RB. Burden, prevention and control of tobacco consumption in Nepal: a narrative review of existing evidence. *Int. health.* 2021;13(2):110-121. doi:[10.1093/inthealth/ihaa055](https://doi.org/10.1093/inthealth/ihaa055)
- Aryal UR, Bhatta DN, Shrestha N, Gautam A. Assessment of nicotine dependence among smokers in Nepal: a community-based cross-sectional study. *Tob. Ind. Dis.* 2015;13(1):1-8. doi:[10.1186/s12971-015-0053-8](https://doi.org/10.1186/s12971-015-0053-8)
- National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Preventing tobacco use among youth and young adults: A report of the surgeon general. Atlanta (GA): Centers for Disease Control and Prevention (US); 2012. Accessed July 25, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK99237/>
- Teimourpour A, Farzadfar F, Yaseri M, Hosseini M. Spatial survival analysis of initiation age and prevalence of smoking in Iran; results from a population-based study. *Arch. Iran. Med.* 2020;23(7):462-468. doi:[10.34172/aim.2020.43](https://doi.org/10.34172/aim.2020.43)
- Hegmann KT, Fraser AM, Keaney RP, et al. The effect of age at smoking initiation on lung cancer risk. *Epidemiology.* 1993;444-448. doi:[10.1097/00001648-199309000-00010](https://doi.org/10.1097/00001648-199309000-00010)
- Huxley RR, Yatsuya H, Lutsey PL, Woodward M, Alonso A, Folsom AR. Impact of age at smoking initiation, dosage, and time since quitting on cardiovascular disease in African Americans and Whites: the atherosclerosis risk in communities study. *Am. J. Epidemiol.* 2012;175(8):816-826. doi:[10.1093/aje/kwr391](https://doi.org/10.1093/aje/kwr391)
- Kashyap R, Hock LM, Bowman TJ. Higher prevalence of smoking in patients diagnosed as having obstructive sleep apnea. *Sleep Breath.* 2001;5(04):167-172. doi:[10.1007/s11325-001-0167-5](https://doi.org/10.1007/s11325-001-0167-5)
- Shrestha N, Mehata S, Pradhan PMS, Joshi D, Mishra SR. A nationally representative study on socio-demographic and geographic correlates, and trends in tobacco use in Nepal. *Sci Rep.* 2019;9(1):1-11. doi:[10.1038/s41598-019-39635-y](https://doi.org/10.1038/s41598-019-39635-y)
- Sreeramareddy CT, Ramakrishnareddy N, Harsha Kumar H, Sathian B, Arokiasamy JT. Prevalence, distribution and correlates of tobacco smoking and chewing in Nepal: a secondary data analysis of Nepal Demographic and Health Survey-2006. *Subst. Abuse: Treat. Prev. Policy.* 2011;6(1):1-9. doi:[10.1186/1747-597x-6-33](https://doi.org/10.1186/1747-597x-6-33)
- Baig SA. Bayesian inference: An introduction to hypothesis testing using Bayes factors. *Nicotine. Tob. Res.* 2020;22(7):1244-1246. doi:[10.1093/ntr/ntz207](https://doi.org/10.1093/ntr/ntz207)
- Kelter R. Bayesian alternatives to null hypothesis significance testing in biomedical research: a non-technical introduction to Bayesian inference with JASP. *BMC. Med. Res. Methodol.* 2020;20(1):1-12. doi:[10.1186/s12874-020-00980-6](https://doi.org/10.1186/s12874-020-00980-6)
- Van De Schoot R, Depaoli S. Bayesian analyses: where to start and what to report. *The Eur. Health Psycho.* 2014;16(2):75-84.
- Wagenmakers E-J, Love J, Marsman M, Jamil T, Ly A, Verhagen J, et al. Bayesian inference for psychology. Part II: Example applications with JASP. *Psychon Bull Rev.* 2018;25(1):58-76. doi:[10.3758/s13423-017-1323-7](https://doi.org/10.3758/s13423-017-1323-7)
- West R. Using Bayesian analysis for hypothesis testing in addiction science. *Addiction.* 2016;111(1):3-4. doi:[10.1111/add.13053](https://doi.org/10.1111/add.13053)
- Head ML, Holman L, Lanfear R, Kahn AT, Jennions MD. The extent and consequences of p-hacking in science. *PLoS Biol.* 2015;13(3):e1002106. doi:[10.1371/journal.pbio.1002106](https://doi.org/10.1371/journal.pbio.1002106)
- Bettis RA. The search for asterisks: compromised statistical tests and flawed theories. *Strategic Management Journal.* 2012;33(1):108-113. doi:[10.1002/smj.975](https://doi.org/10.1002/smj.975).
- Crane H. The impact of P-hacking on "redefine statistical significance". *Basic Appl Soc Psych.* 2018;40(4):219-235. doi:[10.1080/01973533.2018.1474111](https://doi.org/10.1080/01973533.2018.1474111).
- Dhimal M, Bista B, Bhattarai S, et al. Report of non-communicable disease risk factors: steps survey Nepal 2019. Accessed July 25, 2024. <https://www.who.int/docs/default-source/nepal-documents/ncds/ncd-steps-survey-2019-compressed.pdf6>
- Karki K, Dahal B, Regmi A, Poudel A, Gurung Y. WHO STEPS Surveillance: Non Communicable Diseases Risk Factors Survey. 2008. Kathmandu: Ministry of Health and Population, SOLID Nepal and WHO; 2008. Accessed July 25, 2024. https://cdn.who.int/media/docs/default-source/ncds/ncd-surveillance/datareporting/nepal/steps/nepal_2007_steps_report.pdf?sfvrsn=4929cbb5_5&download=true
- Aryal KK, Neupane S, Mehata S, et al. Non-communicable diseases risk factors: STEPS Survey Nepal 2013. Accessed July 25, 2024. <https://nhrc.gov.np/wp-content/uploads/2017/02/noncommunicable-disease-report-2012-2013.pdf>
- Bista B, Dhimal M, Bhattarai S. Prevalence of non-communicable diseases risk factors and their determinants: results from STEPS survey 2019, Nepal. *PLoS One.* 2021;16(7):e0253605. doi:[10.1371/journal.pone.0253605](https://doi.org/10.1371/journal.pone.0253605)
- Page R, Satake E. Beyond p values and hypothesis testing: using the minimum bayes factor to teach statistical inference in undergraduate introductory statistics courses. *Educ Learn.* 2017;6(4):254-266. doi:[10.5539/jel.v6n4p254](https://doi.org/10.5539/jel.v6n4p254)
- Ruiz-Ruano García AM, López Puga J. Deciding on null hypotheses using p-values or bayesian alternatives: a simulation study. *Psicothema.* 2018;30(1):110-115. doi:[10.7334/psicothema2017.308](https://doi.org/10.7334/psicothema2017.308)
- Van Doorn J, van den Bergh D, Böhm U, et al. The JASP guidelines for conducting and reporting a Bayesian analysis. *Psychon Bull Rev.* 2021;28(3):813-826. doi:[10.3758/s13423-020-01798-5](https://doi.org/10.3758/s13423-020-01798-5)
- Goss-Sampson M. Statistical analysis in JASP: A guide for students. London: University of Greenwich; 2019. Accessed

- July 25, 2024. <https://static.jasp-stats.org/Statistical%20Analysis%20in%20JASP%20v0.10.0-%2.pdf>
28. Allen M, Poggiali D, Whitaker K, Marshall TR, Kievit RA. Raincloud plots: a multi-platform tool for robust data visualization. *Wellcome Open Res.* 2019;4(63). doi:[10.12688/wellcomeopenres.15191.1](https://doi.org/10.12688/wellcomeopenres.15191.1)
 29. Alzahrane A, West R, Ubhi HK, Brown J, Abdulqader N, Samarkandi O. Evaluations of clinical tobacco cessation interventions in Arab populations: a systematic review. *Addict. Behav.* 2019;88:169-174. doi:[10.1016/j.addbeh.2018.08.017](https://doi.org/10.1016/j.addbeh.2018.08.017)
 30. Boffo M, Zerhouni O, Gronau Q, Beek RJ, Nikolaou, Marsman M, Wier R. Cognitive bias modification for behavior change in alcohol and smoking addiction: bayesian meta-analysis of individual participant data. *Neuropsychol Rev.* 2019;29(1):52-78. doi:[10.1007/s11065-018-9386-4](https://doi.org/10.1007/s11065-018-9386-4)
 31. Bhatta DN, Crosbie E, Bialous SA, Glantz S. Defending comprehensive tobacco control policy implementation in Nepal from tobacco industry interference (2011–2018). *Nicotine. Tob. Res.* 2020;22(12):2203-2212. doi:[10.1093/ntr/ntaa067](https://doi.org/10.1093/ntr/ntaa067)
 32. Bhatta D, Crosbie E, Bialous S, Glantz S. Tobacco control in Nepal during a time of government turmoil (1960–2006). *Tob Control.* 2020;29(5):548-555. doi:[10.1136/tobaccocontrol-2019-055066](https://doi.org/10.1136/tobaccocontrol-2019-055066)
 33. Bhatta DN, Bialous S, Crosbie E, Glantz S. Exceeding WHO Framework Convention on Tobacco Control (FCTC) obligations: Nepal overcoming tobacco industry interference to enact a comprehensive tobacco control policy. *Nicotine Tob Res.* 2020;22(12):2213-2223. doi:[10.1093/ntr/ntz177](https://doi.org/10.1093/ntr/ntz177)
 34. Dienes Z, Mclatchie N. Four reasons to prefer Bayesian analyses over significance testing. *Psychon Bull Rev.* 2018;25(1):207-218. doi:[10.3758/s13423-017-1266-z](https://doi.org/10.3758/s13423-017-1266-z)
 35. Reitsma MB, Flor LS, Mullany EC, Gupta V, Hay SI, Gakidou E. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and initiation among young people in 204 countries and territories, 1990–2019. *Lancet Public Health.* 2021;6(7):e472-e81. doi:[10.1016/s2468-2667\(21\)00102-x](https://doi.org/10.1016/s2468-2667(21)00102-x)
 36. Odukoya OO, Odeyemi KA, Oyeyemi AS, Upadhyay RP.

Determinants of smoking initiation and susceptibility to future smoking among school-going adolescents in Lagos State, Nigeria. *Asian Pac J Cancer Prev.* 2013;14(3):1747-1753. doi:[10.7314/APJCP.2013.14.3.1867](https://doi.org/10.7314/APJCP.2013.14.3.1867)

ACKNOWLEDGEMENTS

We would like to acknowledge everyone who took part in this survey for their efforts. We are grateful to the NHRC team for providing us with valuable data for this study.

CONFLICT OF INTEREST

The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.

FUNDING

There was no source of funding for this research.

ETHICAL APPROVAL AND INFORMED CONSENT

This study utilized secondary data obtained from the three STEPS Surveys of Nepal (2008, 2013 and 2019) which are publicly available and do not contain any personally identifiable information. All sources have been properly cited in the manuscript and followed the ethical guidelines.

All STEPS Surveys had mentioned obtaining ethical clearance from the Ethical Review Board of the Nepal Health Research Council. The surveys had maintained all ethical issues.

DATA AVAILABILITY

The data supporting this research are available from the authors on reasonable request.

AUTHORS' CONTRIBUTIONS

URA: wrote the manuscript and performed statistical analysis. DB and YS: critically revised the manuscript and provided valuable input. BB: arranged the data and revised the manuscript. MD and PG: revised final version of the manuscript. All authors read and approved the final version of the manuscript.

PROVENANCE AND PEER REVIEW

Not commissioned; externally peer reviewed.